Sober Witchcraft Retreat Comes to New Orleans, Seeking Local Sponsors for Spiritual Recovery Event
The Awakening Hope Retreat calls on local businesses and organizations to partner in creating a public ritual focused on healing from addiction.
'I created this retreat to honor recovery as sacred. I'm seeking partners who love New Orleans and believe in healing through community, ritual, and magick.'— Sunshine Witchski - Host of Retreat
NEW ORLEANS, LA, UNITED STATES, May 23, 2025 / EINPresswire.com / -- In March 2026, a unique and powerful event will take place in New Orleans, bringing together recovery and ritual in a way only this city could hold. The Awakening Hope Retreat, hosted by the creators of The Sober Witch Life and the Recovery Coven, is calling on local businesses, spiritual leaders, wellness advocates, and organizations to partner in creating a transformative public ritual focused on healing from addiction through witchcraft.
The retreat, part of a broader movement that integrates witchcraft and sobriety, will culminate in a free community ritual open to the public. Organizers are currently seeking sponsors for venue space, food, and giveaways, and partners to help promote the event locally and invite the community into this magickal and meaningful experience.
WHY THIS MATTERS NOW
According to the Substance Abuse and Mental Health Services Administration, nearly 50 million Americans struggle with substance use disorders. In Louisiana alone, over 700,000 residents are impacted by addiction, with countless families and communities feeling the ripple effects. Traditional recovery approaches often leave out those whose healing is deeply spiritual or alternative in nature.
The Awakening Hope Retreat offers something different. By blending spiritual recovery programs with ancestral ritual, intuitive tools, and shadow work, it creates space for individuals who identify as witches, seekers, or healers to reclaim recovery on their own terms.
This event not only provides a pathway for personal transformation but also invites the larger New Orleans community to participate in a public act of healing. Partners and sponsors will be recognized in all promotional materials and honored with blessings of gratitude and abundance during the ritual itself.
WHAT THE EVENT INCLUDES
The public ritual will take place during the retreat weekend and is expected to draw attendees from both the local area and across the country. The event will feature a spiritually grounded, non-denominational community ritual that is open to the public. Local vendors and spiritual businesses will have opportunities to participate, and the experience will include live music, altar building, and a guided ceremony invoking healing from addiction. Witch's recovery tools, such as spellwork, ancestral offerings, and sacred circle practices, will be integrated into the experience.
This event honors the spirit of New Orleans and aims to incorporate its rich cultural history of ritual, mysticism, and community healing. It is also designed to be inclusive, welcoming not just witches but anyone impacted by addiction who desires to witness or participate in a spiritually led path to hope and wholeness.
WHO IS SUNSHINE?
Sunshine is the founder of The Sober Witch Life, a global movement centered on addiction recovery for witches. She is a Reiki Master Teacher, psychic medium, and spiritual mentor with over 5.5 years of sobriety. Through her work in the Recovery Coven and the Sober Witch Mobile App, Sunshine has helped hundreds of witches in recovery access magickal recovery tools, find community, and reclaim their power.
She is also the author of Sober Witch Life: A Magickal Guide to Recovery, and has led dozens of workshops and rituals that blend witchcraft, spiritual education, and real recovery practices.
'New Orleans is my second favorite place to call home,' Sunshine shared. 'My love for this city runs deep, and I hope to spend many days loving and honoring it. This retreat is only the beginning of a long relationship between my work and this incredible place.'
A PATH THAT FEELS LIKE HOME
Unlike traditional 12-step programs or clinical rehab, The Sober Witch Life framework integrates witchcraft practices like divination, full moon rituals, candle magick, energy healing, and spiritual shadow work. It meets people where they are, especially those who have felt excluded or misunderstood by mainstream recovery options.
Dani, a Recovery Coven member, shared her story: 'It wasn't until I lit a candle and called on my ancestors that I felt something real shift in me. I'd done therapy, tried AA, but I still felt lost. This path gave me my power back.'
The Awakening Hope Retreat channels this power into an in-person experience, allowing both participants and the local community to witness the sacred act of choosing recovery through spiritual connection.
WHAT PARTNERS AND SPONSORS WILL GAIN
Sunshine and her team are seeking support to ensure the event is as impactful and accessible as possible. Partnering organizations will receive recognition in all print and digital promotional materials. They will be acknowledged during the community ritual, receive a ritual blessing of gratitude and abundance on behalf of the Recovery Coven, and be included in a follow-up blog feature and social media campaign. Supporting this event also offers a unique opportunity to advocate for witchcraft and sobriety as a legitimate and effective path to healing.
Ideal partners include businesses or organizations with ties to New Orleans, a love for spiritual healing, or a history of supporting recovery initiatives. Potential supporters may include wellness centers, independent bookstores, food and drink vendors, spiritual shops, performance groups, and recovery-friendly organizations.
A CALL TO NEW ORLEANS
New Orleans is no stranger to ritual. Its reputation as a spiritual city—rooted in African diasporic traditions, Catholicism, voodoo, and folk magick—makes it the perfect setting for this new kind of recovery retreat. Sunshine's team is committed to creating something that uplifts both the national sober witch community and the spirit of New Orleans itself.
They are particularly interested in working with venue partners who can provide space for the public ritual gathering, food and beverage sponsors who can help nourish the attendees, organizations or individuals who can donate items for giveaways or ritual use (such as crystals, incense, candles, or journals), and media or promotion partners who can help share the word within New Orleans.
'We know that healing happens faster and deeper when it happens in community,' Sunshine said. 'This retreat is about more than just sobriety. It's about awakening joy, reclaiming power, and weaving hope back into the fabric of our lives. And New Orleans is the perfect place to begin that work.'
HOW TO GET INVOLVED
The retreat is scheduled for March 2026, with the public ritual taking place during that weekend. Anyone interested in partnership, sponsorship, or participation is encouraged to reach out now while planning is still underway.
For details on how to support The Awakening Hope Retreat please email [email protected]
ABOUT THE SOBER WITCH LIFE
The Sober Witch Life is a spiritual recovery movement offering sober witches and seekers an aligned path to healing. Through the Sober Witch Mobile App, the Recovery Coven, and guided tools for shadow work in recovery, Sunshine has empowered a growing global community of witches in recovery. Her work is redefining what sobriety can look and feel like—and proving that witch-friendly recovery programs can be both effective and joyful.
Sunshine Witchski
Illuminate: The Unschool of Sober Witchcraft
+1 313-595-4148
email us here
Visit us on social media:
Facebook
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
Poop at work. It's good for you!
Well+Being Poop at work. It's good for you! June 6, 2025 | 2:52 PM GMT Gastroenterologist Dr. Trisha Pasricha has some tips for whether to poop on company time (yes), whether to wait (no) and how to relax while on the job.
Medscape
an hour ago
- Medscape
Experimental MS Drug Nearly Eliminates Disease Activity
PHOENIX — Frexalimab, a second-generation anti-CD40 ligand monoclonal antibody provides extended tight control of multiple sclerosis (MS) whether measured by relapse or brain imaging at 2-year follow-up, results of an open-label extension (OLE) of a phase 2 trial showed. 'At week 96, there was almost complete suppression of new gadolinium-enhancing lesions with very similar pattern seen with new or enhancing T2 lesions,' said study investigator Stephen Krieger, MD, professor of neurology, Icahn School of Medicine at Mount Sinai, New York City. Two phase 3 international studies with this drug are already enrolling. 'Part of the interest in frexalimab and anti-CD40 therapies is the idea that one can modulate both B- and T-cell activity without cell depletion,' explained Krieger, who presented the long-term open-label data on May 29 at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting. Near Complete Disease Suppression The latest data suggest frexalimab is fulfilling its promise. Over follow-up to date, there has been nearly complete suppression of gadolinium-enhancing (Gd+) lesions on MRI among those taking the dose now being tested in the phase 3 trials. At 2 years, with an annualized relapse rate of 0.08%, 92% of patients were relapse-free. The randomized portion of this phase 2 trial attracted attention when it was published a year ago in The New England Journal of Medicine , but the 2-year results showed that the efficacy and safety observed at 12 weeks persist. In the controlled trial, 129 patients with relapsing MS were randomized to 300-mg, 400-mg, 600-mg, or 1200-mg frexalimab or matching placebos. Suppression of Gd+ lesions was the primary endpoint. At 12 weeks, the adjusted mean of new Gd+ lesions was 1.4 in the combined placebo groups but 0.3 in the 300-mg frexalimab group and 0.2 in the 1200-mg group. Of those who participated in the randomized portion of the phase 2 trial, 97% continued into the long-term OLE. The OLE consisted of two arms: 1200-mg frexalimab administered intravenously every 4 weeks or 300-mg frexalimab administered subcutaneously every 2 weeks. At the end of 2 years, when 82% of those enrolled in the OLE were still on medication, the adjusted mean for new T1-weighted Gd+ lesions ranged from 0.1 to 0.3 across study arms whether on continuous frexalimab or switched from placebo to frexalimab. For those who were initiated on the 1200-mg dose in the controlled portion of the trial and remained on this dose for the OLE, the mean was 0.1. For the secondary endpoint of new or enlarging T2 lesions, the suppression at 2 years was almost the same. Again, the adjusted mean for new lesions across all arms ranged from 0.1 to 0.3. For those receiving the 1200-mg dose, the mean was 0.2. Mean T2 lesion volume increased in the placebo arm but not in the treatment arms during the randomized phase. After entering the OLE, T2 lesion volume fell in placebo patients now on active therapy. In the 1200-mg arm, the fall in lesion volume during the randomized phase continued into the first 24 weeks of the OLE. After 24 weeks, the lesion volume remained suppressed with no return toward baseline. Those initiated on placebo never caught up after switching to frexalimab. Relapse Rare — 2% at 96 Weeks On the 1200-mg dose of frexalimab, only 8% had any relapse recorded over the extended follow-up. In half, there was a single relapse. Only 2% had three or more relapses. While the Expanded Disability Status Scale score declined slightly among placebo patients once started on active therapy, there was no change from baseline through 96 weeks in patients started on any active therapy. As postulated by earlier preclinical and clinical studies, frexalimab had no effect on lymphocyte counts over time. Over the 96-week follow-up, levels of immunoglobulins remained unchanged, according to Krieger who showed graphs with straight lines for these values over the course of the OLE. Due to the potential of suppressing activation of both T and B cells over time, anti-CD40 therapies have long been considered a promising mechanism for control of MS. However, clinical development of first-generation drugs was abandoned because of an association with thromboembolism. 'Frexalimab has been engineered to avoid these events through a change in the Fc receptors with reduces downstream inflammatory events,' said Krieger. The long-term data support this premise. Over 2 years, there was one pulmonary embolism, but this exception was observed in a patient with a viral illness and a genetic predisposition for an inflammatory response, according to Krieger. When surveying other adverse events, 'nothing jumps out' in the OLE relative to the randomized phase. One potential exception is a rise in liver function tests observed in two (4%) patients on the 1200-mg dose. Only one of these patients discontinued therapy, and the levels returned to normal over time in both. The effects of the anti-CD40 mechanism on both the adaptive and innate immune systems suggest frexalimab might offer efficacy for both progressive and relapsing MS. In the ongoing phase 3 program, one of the trials (FREXALT) is enrolling patients with relapsing MS. The other (FREVIVA) is enrolling patients with progressive disease. Fulfilling its Promise Commenting on the results, Amit Bar-Or, MD, Chief of the Multiple Sclerosis Division, the Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, described frexalimab as 'a very interesting drug.' He agreed that the CD40 ligand is a promising target in MS but cautioned that these phase 2 data cannot answer the most interesting questions. This includes the more robust evidence of safety and efficacy from phase 3 trials, but it remains unclear whether the benefits extend beyond controlling relapsing disease. 'I think there is particular interest in whether it will also show extended benefit in progressive MS, and this will be a major focus of interest from the next set of studies,' Bar-Or said.
CBS News
an hour ago
- CBS News
Texas woman dies from brain-eating amoeba after using tap water for sinus rinse
How to stay safe from the brain-eating amoeba Parasite called Naegleria fowleri has been found in several states and is blamed for 3 deaths in the U.S. this year Parasite called Naegleria fowleri has been found in several states and is blamed for 3 deaths in the U.S. this year A Texas woman died from an infection caused by a brain-eating amoeba after using tap water in a nasal irrigation device, according to the Centers for Disease Control and Prevention. A case report from the agency said the woman died of primary amebic meningoencephalitis, or PAM, a rare but often fatal brain infection caused by the Naegleria fowleri organism. The previously healthy 71-year-old developed severe symptoms, including fever, headache and altered mental status, within four days after using the nasal irrigation device, the case report said. Despite medical treatment for a suspected PAM infection, eight days after the symptoms began, she developed seizures and died. The tap water she used for the sinus rinse came from an RV's water system at a campground in Texas, according to the case report. The CDC recommends the use of distilled, sterile or boiled and cooled tap water for nasal irrigation. PAM is also typically associated with recreational water activities, as the amoeba thrives in warm freshwater lakes, rivers and hot springs. Infections can occur if water containing the ameba goes up the nose and to the brain. To reduce your risk, the CDC suggests holding your nose or wearing a nose clip if you are jumping or diving into fresh water or keeping your head above water in hot springs. In rare cases, people have also become infected from pools and splash pads that did not have enough chlorine, the CDC says. You cannot, however, get a Naegleria fowleri infection from swallowing contaminated water or from someone else who is infected.
